Agilent Technologies(A) - 2025 Q2 - Quarterly Results

Financial Performance - Agilent reported revenue of $1.67 billion for Q2 FY 2025, representing a growth of 6.0% reported and 5.3% core compared to Q2 FY 2024[3]. - GAAP net income for Q2 FY 2025 was $215 million, or $0.75 per share, down 29% from $308 million, or $1.05 per share in Q2 FY 2024[4]. - Non-GAAP net income for Q2 FY 2025 was $373 million, or $1.31 per share, up 7% from $356 million, or $1.22 per share in the same quarter last year[4]. - The full-year revenue outlook for FY 2025 is projected to be between $6.73 billion and $6.81 billion, indicating a growth of 3.4% to 4.6% reported[4]. - Q3 FY 2025 revenue outlook is expected to be in the range of $1.645 billion to $1.675 billion, representing an increase of 4.2% to 6.1% reported[4]. - Net income for the six months ended April 30, 2025, was $533 million, a decrease of 18.8% compared to $656 million for the same period in 2024[21]. - Non-GAAP net income for the six months ended April 30, 2025, was $750 million, representing an increase of 1.9% from $736 million in 2024[22]. Segment Performance - The Life Sciences and Diagnostics Markets Group reported Q2 revenue of $654 million, an increase of 8% reported and 3% core year-over-year[6]. - The Agilent CrossLab Group reported Q2 revenue of $713 million, an increase of 7% reported and 9% core year-over-year[6]. - The Applied Markets Group reported Q2 revenue of $301 million, a decrease of 1% reported and flat core year-over-year[7]. - Revenue for the Life Sciences and Diagnostics Markets Segment increased by 8% year-over-year, reaching $654 million in Q2 2025 compared to $604 million in Q2 2024[40]. - Revenue for the Agilent CrossLab Segment grew by 7% year-over-year, totaling $713 million in Q2 2025, up from $664 million in Q2 2024[40]. - The Applied Markets Segment reported a slight decline in revenue of 1%, with $301 million in Q2 2025 compared to $305 million in Q2 2024[40]. Cash Flow and Expenditures - Cash flows from operating activities for the six months ended April 30, 2025, were $652 million, down from $818 million in the same period of 2024[21]. - The company incurred $211 million in capital expenditures for property, plant, and equipment during the six months ended April 30, 2025, compared to $193 million in 2024[21]. - The net cash used in financing activities was $296 million for the six months ended April 30, 2025, a decrease from $531 million in 2024[21]. - The company reported a net cash increase of $157 million for the six months ended April 30, 2025, compared to an increase of $81 million in the same period of 2024[21]. Operational Insights - The gross margin for the Life Sciences and Diagnostics Markets Segment was 52.8% in Q2 2025, down from 55.1% in Q2 2024[35]. - Agilent's Ignite Transformation is driving financial success and operational excellence, becoming the core enterprise delivery engine[5]. Earnings Per Share - Non-GAAP EPS for Q3 FY 2025 is expected to be in the range of $1.35 to $1.37 per share[4].